Hereditary breast cancer genes: BRCA1, BRCA2 and PALB2
In one sentence
Hereditary breast cancer genes are genes in which certain inherited harmful variants increase the chance of developing breast cancer.
The intuition
Think of a maintenance manual passed between generations. A harmful change in one instruction can make some repairs harder. It does not mean the building must fail. This analogy also has a limit: inherited cancer risk reflects many biological and environmental influences, rather than a single broken instruction.
The important words are certain harmful variants. Having a gene is normal; having a particular risk-associated version is the finding. [1]
How it works
BRCA1 and BRCA2 encode proteins involved in repairing damaged DNA, or deoxyribonucleic acid. PALB2 means partner and localizer of BRCA2. Its protein helps BRCA2 function at the places where repair occurs. These proteins participate in homologous recombination, which uses a matching DNA copy during repair. Their jobs overlap, but the proteins are not interchangeable. [1, 2]
A germline variant can be passed through eggs or sperm. A person can inherit one harmful copy while retaining a working copy. Additional changes in a cell lineage can later compromise repair and contribute to cancer. Inherited susceptibility and the eventual tumor's repair state are therefore separate questions. [1]
The three genes also have different cancer-risk profiles. Yang and colleagues' study of 524 PALB2 families established associations with breast cancer and several other cancers. Its family-based estimates depended on age and the study's modeling of family history and ascertainment. They are evidence that PALB2 is a susceptibility gene, rather than a fixed probability for everyone carrying any PALB2 variant. [3]
Why it matters in cancer
The result may help explain inherited susceptibility and questions about relatives. It does not establish that every cancer in a family had the same cause. Nor does a family's lack of known cancer exclude a harmful inherited variant. Family size, ages and incomplete information affect what a family history shows. [1, 4]
Inherited-risk evidence is also distinct from a tumor's treatment biomarker. A tumor-only BRCA finding does not establish inheritance. A confirmed inherited variant does not, by itself, measure current repair function or guarantee a drug response. See BRCAness for that second layer.
How it is measured
Read the variant classification together with the test scope:
| Field | What to check |
|---|---|
| Input | Usually blood or saliva for germline testing; this need not consume a tumor block |
| Method | Which genes and variant types were assessed, with a named laboratory method |
| Output | A precisely named variant and classification, such as pathogenic, likely pathogenic or uncertain significance |
| Interpretation | Evidence about that variant's relationship to disease; a gene name alone is insufficient |
| Limits | Untested regions, technically missed changes and uncertainty in variant interpretation; the result is not a direct tumor-function assay |
A variant of uncertain significance (VUS) has insufficient evidence to classify it as harmful or harmless. It is not equivalent to a pathogenic finding. These categories describe evidence about a variant, not the severity of someone's existing cancer. [4]
Common confusions
- Inherited susceptibility is not inevitability. A pathogenic result cannot tell whether or when a person will develop cancer. [1]
- BRCA-negative is not a complete family-risk assessment. Other genes and non-genetic influences may matter; a negative result has a defined testing scope. [4]
- Inherited and acquired changes differ. The same gene can be altered in a tumor without a constitutional inherited finding.
- Similar repair roles do not make all gene results equivalent. Keep the exact gene, variant classification, specimen and question attached.
Try it
Fictional reports: Alex has a pathogenic PALB2 variant confirmed by germline testing. Sam has a PALB2 VUS. Jo has a BRCA2 variant found only in tumor sequencing. Can all three be labeled as having a confirmed hereditary susceptibility finding?
Answer: Only Alex's report establishes that finding. Sam's classification is uncertain. Jo's result needs evidence about origin and classification. None of the reports supplies an individual cancer forecast or a guaranteed treatment response.
Explain it back
“A hereditary-risk result needs a ___ variant in a ___ context.” One answer: “pathogenic or likely pathogenic / confirmed germline testing.” Add why the gene name alone is not enough.
Takeaway
Keep inherited origin, variant classification and tumor function as three separate pieces of evidence.
Related concepts
Sources
Source check: October 10, 2026. Examples are fictional; expert and learner review remain pending.
References
- NCI: BRCA gene changes, cancer risk and genetic testing — inherited susceptibility and limits of positive and negative findings.
- Xia et al., 2006 (PMID 16793542) — primary experiments identifying PALB2's partnership with BRCA2; abstract checked.
- Yang et al., 2020 (PMID 31841383) — international family study of germline PALB2 pathogenic variants; abstract checked.
- NCI: genetic testing for inherited cancer risk — family context, multigene testing and result categories.